Short answer
PRECIGEN, INC. (PGEN) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026.
PRECIGEN, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026
- Investor focus: quarterly performance metrics, cash position and management commentary in the attached earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 PAPZIMEOS revenue $72.9M, up 37% sequentially, confirming accelerating commercial adoption
- Positive operating cash flow $11.9M, one quarter ahead of guidance, reducing near-term financing pressure
- Net income $35.8M, or $0.08 diluted EPS, versus $325.3M attributable loss in Q3 2025
- Cash, equivalents and investments $51.0M at September 30, against $94.3M long-term debt
- FDA AdenoVerse Platform Technology Designation could streamline development across future therapies beyond PAPZIMEOS
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PRECIGEN, INC. 8-K filings
Get the next PGEN 8-K as it lands
Follow PGEN for push alerts, or ask the research agent what this filing means.